Genfit: Milestone Achieved as a Compound Developed in Partnership Enters the Clinic
News May 06, 2010
Thanks to the joint efforts of the research teams of the two companies, a ‘first-in-class’ compound with an original mechanism of action for the treatment of cardiometabolic disorders is today entering clinical trials.
Jean-François Mouney, Chairman of GENFIT’s Management Board, declared: “We are very pleased to see a molecule originating from one of our research partnerships successfully achieve an important phase in its development. This provides strong recognition by the pharmaceutical industry of our scientific expertise and of the relevance of our research targets. This is the second program to enter clinical trials from this strategic collaboration initiated 8 years ago. This new achievement underlines the talent of our research teams, as well as those of our partner. We are confident that our innovative and collaborative approach will provide an efficient therapeutic strategy for cardiometabolic diseases and associated causes of mortality and morbidity.”
In addition to this initial milestone, GENFIT will potentially receive further clinical development-based milestone payments, as well as royalties on future sales.
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Brian Berridge Set to Manage National Toxicology ProgramNews
The National Toxicology Program (NTP) has named Brian Berridge, D.V.M., Ph.D., as its new Associate Director. Berridge, formerly of GlaxoSmithKline, will oversee day-to-day operations as NTP coordinates toxicology research and testing across nine different federal agencies.READ MORE
Safety and Efficacy of MERS Treatment Confirmed in Phase I TrialNews
An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.READ MORE